Skip to main content
. 2010 Jan 25;159(4):856–871. doi: 10.1111/j.1476-5381.2009.00581.x

Figure 5.

Figure 5

Intraperitoneal administration of deoxyelephantopin (DET) suppresses orthotopic TS/A mammary tumour growth in female BALB/c mice. Experimental design and details are in Figure S1A. In (A1) and (A2), tumour growth was measured once a week (days 7–28) in the eight experimental groups. At the end of the study, tumours were excised and processed for immunohistochemical staining for tumour growth with proliferating cell nuclear antigen (PCNA) in (B), tumour blood vessel growth with CD31 in (C) and apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay in (D). A representative image of each treatment group is shown. PCNA-positive cells (%) calculated by [(number of positive (red) cells/total number of cells counted) ×100]. Relative CD31-positive areas (%) calculated by [(areas of positive (red) CD31 in treatment group/areas of positive CD31 in tumour group) ×100]. TUNEL-postive cells in (D) calculated by number of positive (reddish brown) cells. Data are mean ± SEM of six independent tumour samples from each group of mice (*P < 0.05; **P < 0.005).